Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

12.5

Margin Of Safety %

Put/Call OI Ratio

0.54

EPS Next Q Diff

-0.21

EPS Last/This Y

0.52

EPS This/Next Y

-0.93

Price

23.79

Target Price

67.1

Analyst Recom

1.33

Performance Q

-19.99

Relative Volume

0.8

Beta

1.61

Ticker: CLDX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-12-19CLDX25.40.524.5018551
2024-12-20CLDX25.150.520.1118543
2024-12-23CLDX24.790.521.3018060
2024-12-24CLDX25.130.530.0118195
2024-12-26CLDX25.620.510.0518703
2024-12-27CLDX25.380.490.5319234
2024-12-30CLDX25.150.490.0019246
2024-12-31CLDX25.260.490.3219245
2025-01-02CLDX25.940.490.1219343
2025-01-03CLDX26.820.490.9319383
2025-01-06CLDX26.560.521.8421543
2025-01-07CLDX27.760.494.4721305
2025-01-08CLDX26.540.544.6322924
2025-01-09CLDX26.530.544.6322924
2025-01-10CLDX24.340.545.1022881
2025-01-13CLDX24.30.560.1123526
2025-01-14CLDX22.910.550.0323726
2025-01-15CLDX22.610.546.1523707
2025-01-16CLDX22.710.553.3023737
2025-01-17CLDX23.80.540.4423825
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-12-19CLDX25.37-22.7-81.1-2.40
2024-12-20CLDX25.16-22.7-67.2-2.40
2024-12-23CLDX24.77-22.7-64.4-2.40
2024-12-24CLDX25.13-22.7-77.7-2.40
2024-12-26CLDX25.65-22.7-80.5-2.40
2024-12-27CLDX25.40-22.7-66.7-2.40
2024-12-30CLDX25.09-22.7-65.9-2.40
2024-12-31CLDX25.26-22.7-73.6-2.40
2025-01-02CLDX25.81-22.7-80.6-2.40
2025-01-03CLDX26.85-22.7-89.2-2.40
2025-01-06CLDX26.59-22.7-67.6-2.40
2025-01-07CLDX27.57-22.7-87.1-2.40
2025-01-08CLDX26.53-22.7-55.1-2.40
2025-01-09CLDX26.53-22.7-71.2-2.40
2025-01-10CLDX24.35-22.7-36.0-2.40
2025-01-13CLDX24.30-22.7-70.2-2.40
2025-01-14CLDX22.92-22.7-44.7-2.40
2025-01-15CLDX22.64-22.7-64.7-2.40
2025-01-16CLDX22.75-22.7-73.9-2.40
2025-01-17CLDX23.79-22.7-93.1-2.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-12-19CLDX0.703.6311.90
2024-12-20CLDX0.703.6311.90
2024-12-23CLDX0.713.6311.90
2024-12-24CLDX0.713.6311.90
2024-12-26CLDX0.693.6311.30
2024-12-27CLDX0.693.6311.30
2024-12-30CLDX0.713.6011.30
2024-12-31CLDX0.713.6011.30
2025-01-02CLDX0.703.6011.30
2025-01-03CLDX0.703.6011.30
2025-01-06CLDX0.683.6011.30
2025-01-07CLDX0.683.6011.30
2025-01-08CLDX0.703.6011.30
2025-01-09CLDX0.703.6011.30
2025-01-10CLDX0.703.6011.30
2025-01-13CLDX0.703.6612.50
2025-01-14CLDX0.703.6612.50
2025-01-15CLDX0.703.6612.50
2025-01-16CLDX0.703.6612.50
2025-01-17CLDX0.703.6612.50
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.64

Avg. EPS Est. Current Quarter

-0.73

Avg. EPS Est. Next Quarter

-0.85

Insider Transactions

0.7

Institutional Transactions

3.66

Beta

1.61

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

Fair Value

Quality Score

25

Growth Score

38

Sentiment Score

2

Actual DrawDown %

58.4

Max Drawdown 5-Year %

-63.6

Target Price

67.1

P/E

Forward P/E

PEG

P/S

158.08

P/B

2.01

P/Free Cash Flow

EPS

-2.57

Average EPS Est. Cur. Y​

-2.4

EPS Next Y. (Est.)

-3.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1544.48

Relative Volume

0.8

Return on Equity vs Sector %

-38.7

Return on Equity vs Industry %

-26.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

-93.1
Celldex Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 160
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today
news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance
stock history CLDX – Celldex Therapeutics, Inc. invest stock market
stock prices CLDX premarket after hours
ticker CLDX fair value insiders trading